NovaBridge Biosciences (NasdaqGM: NBP)
Health Care · Biotechnology · US
$1.32
-5.38% today · -77.2% 1Y
NovaBridge Biosciences (NasdaqGM: NBP) operates in the Biotechnology industry within the Health Care sector. The company is valued at $153.12M and employs 30 people.
Over the last twelve months the share price has lost 77.2%, trading between 1.31 and 6.79.
Tweenvest scores NovaBridge Biosciences across four factors: quality 39/100, value 60/100. Its strongest factor is value.
NBP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $153.12M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.04
- Dividend yield
- —
- Beta (5Y)
- 1.60
- 52-week high
- $6.79
- 52-week low
- $1.31
- Avg volume (3M)
- —
- Shares outstanding
- 116.00M
- Employees
- 30
- Next earnings
- —
About NovaBridge Biosciences
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
- ISIN
- US44975P1030
- Founded
- 2014
- Listed since
- Jan 17, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Helixmith Co., LtdKOSDAQ: A084990 | $155.16M | ₩4,530.00 | +22.60% |
| Innovacell Inc.TSE: 504A | $155.13M | ¥544.00 | -9.63% |
| Mycenax Biotech Inc.TPEX: 4726 | $154.11M | NT$23.80 | +2.59% |
| Tiziana Life Sciences LtdNasdaqCM: TLSA | $153.88M | $1.09 | -8.40% |
| BioInvent International AB (publ)OM: BINV | $152.68M | Skr23.10 | -0.43% |
| Minerva Neurosciences, Inc.NasdaqCM: NERV | $151.84M | $2.89 | -9.12% |
| Essex Bio-Technology LimitedSEHK: 1061 | $149.73M | HK$2.08 | -3.26% |
| Scancell Holdings plcAIM: SCLP | $149.18M | £0.09 | +0.54% |
Figures last refreshed Oct 11, 2026.